Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas

Acta Neuropathologica

Volumn 103, Issue 3, 2002, Pages 267-275

  Watanabe, Takao ^a   Nakamura, Mitsutoshi ^a   Kros, Johan M ^b   Burkhard, Christoph ^c   Yonekawa, Yasuhiro ^c   Kleihues, Paul ^a   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Astrocytoma; Chromosome arm 1p and 19q; Loss of heterozygosity; Methylation; MGMT; Oligodendroglioma; TP53 mutation

Indexed keywords

ALKYLATING AGENT; DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CELL NUCLEUS; CHROMOSOME 19Q; CHROMOSOME 1P; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE MARKER; DNA REPAIR; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROMORPHOLOGY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; REVIEW; TUMOR CELL; TUMOR DIFFERENTIATION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ASTROCYTOMA; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENES, P53; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; OLIGODENDROGLIOMA; PHENOTYPE;

EID: 0036938633     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004010100464     Document Type: Review

References (53)

1. Bello MJ, Leone PE, Nebreda P, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Garcia Miguel P, Queizan A, Hernandez Moneo JL, et al. (1995) Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 83: 160-164
2. Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Pestana A, Rey JA (1995) Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64:207-210
3. Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD (1999) Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155:375-386
4. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479
5. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1393
6. Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP (1997) Oligodendrogliomas. I. Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol 34:37-59
7. Donahue B, Scott CB, Nelson JS, Rotman M, Murray KJ, Nelson DF, Banker FL, Earle JD, Fischbach JA, Asbell SO, Gaspar LE, Markoe AM, Curran W (1997) Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys 38:911-914
8. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
9. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797
10. Forsyth PA, Roa WH (1999) Primary central nervous system tumors in adults. Curr Treat Options Neurol 1:377-394
11. Fortin D, Cairncross GJ, Hammond RR (1999) Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 45:1279-1291
12. Fujisawa H, Kurrer M, Reis RM, Yonekawa Y, Kleihues P, Ohgaki H (1999) Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with LOH on chromosome 10q25-qter. Am J Pathol 155:387-394
13. Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B (1992) The treatment of oligodendrogliomas and mixed oligodendroglioma- astrocytomas with PCV chemotherapy. J Neurosurg 76:741-745
14. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826
15. Husemann K, Wolter M, Buschges R, Bostrom J, Sabel M, Reifenberger G (1999) Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2 C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 58:1041-1050
16. Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, France
17. Kleihues P, Davis RL, Ohgaki H, Cavenee WK (1997) Low-grade diffuse astrocytomas. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, France, pp 10-14
18. 6-methylguanine from rat liver DNA. Nature 259:153-155
19. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, von Deimling A (1995) Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54:91-95
20. Kros JM, de Jong AA, van der Kwast TH (1992) Ultrastructural characterization of transitional cells in oligodendrogliomas. J Neuropathol Exp Neurol 51:186-193
21. Kros JM, Schouten WC, Janssen PJ, van der Kwast TH (1996) Proliferation of gemistocytic cells and glial fibrillary acidic protein (GFAP)-positive oligodendroglial cells in gliomas: a MIB-1/GFAP double labeling study. Acta Neuropathol 91:99-103
22. Kros JM, Van Eden CG, Stefanko SZ, Waayer-Van Batenburg M, van der Kwast TH (1990) Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas. Cancer 66:1204-1212
23. Krouwer HG, Davis RL, Silver P, Prados M (199 1) Gemistocytic astrocytomas: a reappraisal. J Neurosurg 74:399-406
24. Linskey ME, Gilbert MR (1995) Glial differentiation: a review with implications for new directions in neuro-oncology. Neurosurgery 36:1-21
25. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, von Deimling A (1997) Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56: 1098-1104
26. Mason WP, Krol GS, DeAngelis LM (1996) Low-grade oligodendroglioma responds to chemotherapy. Neurology 46:203-207
27. Arf deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11:159-168
28. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter hypermethylation of the DNA repair gene MGTM in astrocytomas is frequently associated with G:CA:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22:1715-1719
29. Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 59:539-543
30. Noble M, Gutowski N, Bevan K, Engel U, Linskey M, Urenjak J, Bhakoo K, Williams S (1995) From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte-type-2 astrocyte lineage. Glia 15:222-230
31. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P (1991) p53 mutations in nonastrocytic human brain tumors. Cancer Res 51:6202-6205
32. Ohgaki H, Schauble B, zur Hausen A, von Ammon K, Kleihues P (1995) Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 427: 113-118
33. 6-alkylguanine by alkyltransferases. Mutat Res 462:83-100
34. 6-methylguanine-DNA methyltransferase gene. Cancer Res 57:3672-3677
35. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP (2000) Oligoastrocytoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, France, pp 65-67
36. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175-1190
37. Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, Niederacher D, Wechsler W, Reifenberger G (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 55:822-831
38. Rosenberg JE, Lisle DK, Burwick JA, Ueki K, von Deimling A, Mohrenweiser HW, Louis DN (1996) Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 13:2483-2485
39. Russell DS, Rubinstein LJ (1989) Pathology of tumours of the nervous system. Edward Arnold, London
40. Schiffer D (1997) Brain tumors. Biology, pathology, and clinical references. Springer, Berlin
41. 6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 58:1068-1073
42. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O'Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins RB (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144-4152
43. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645
44. Streffer J, Schabet M, Bamberg M, Grote EH, Meyermann R, Voigt K, Dichgans J, Weller M (2000) A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurol 247:297-302
45. von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, Jahnke R, Kaskel P, Duerr EM, Koopmann J, Maintz D, Steinbeck S, Wick W, Platten M, Müller DJ, Przkora R, Waha A, Blümcke B, Wellenreuther R, Meyer-Puttlitz B, Schmidt O, Mollenhauer J, Poustka A, Stangl AP, Lenartz D, von Ammon K (2000) Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 59:544-558
46. von Deimling A, Nagel J, Bender B, Lenartz D, Schramm J, Louis DN, Wiestler OD (1994) Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 57:676-680
47. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H (1997) Incidence and timing of p53 mutations during astrocytoma progression in patients With multiple biopsies. Clin Cancer Res 3:523-530
48. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217-224
49. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H (1997) Role of gemistocytes in astrocytoma progression. Lab Invest 76:277-284
50. Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H (2001) Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol (in press)
51. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17:5612-5619
52. Wondrusch E, Huemer M, Budka H (199 1) Production of glial fibrillary acidic protein (GFAP) by neoplastic oligodendrocytes. Gliofibrillary oligodendroglioma and transitional astrocytoma revisited. Brain Tumor Pathol 8:11-15
53. Yong WH, Chou D, Ueki K, Harsh GR, von Deimling A, Gusella JF, Mohrenweiser HW, Louis DN (1995) Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112. J Neuropathol Exp Neurol 54:622-626